Review



brain cancer cell line model ln 229  (Human Protein Atlas)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Human Protein Atlas brain cancer cell line model ln 229
    GAL3ST4 drives Siglec-7 ligand expression in glioma cells (A–C) Graphs depict Kaplan-Meier survival analysis for (A) low-grade glioma (LGG) patients with either high or low mRNA expression of the GAL3ST4 gene, (B) LGG patients with either a high or low chromosomal copy number at the GAL3ST4 locus, and (C) LGG patients with either high or low DNA methylation at the GAL3ST4 promoter. (D) The biosynthetic pathway for either sialylation (ST3GAL1/2) or sulfation (GAL3ST4) of core 1 O-linked glycans is depicted. (E) The average mRNA expression of ST3GAL1, ST3GAL2, and GAL3ST4 across 14 different cancer types is shown. (F) Representative flow cytometry plot depicts staining of the <t>indicated</t> <t>LN-229</t> cell lines with PNA. (G) Representative flow cytometry plot depicts staining of the indicated LN-229 cell lines with Siglec-7-Fc. (H) Representative flow cytometry plots depict staining of sialidase-treated LN-229 cells with Siglec-7-Fc. (I) The potential structure of a novel sulfated Siglec-7 ligand is depicted.
    Brain Cancer Cell Line Model Ln 229, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brain+cancer+cell+line+model+ln+229/pmc13069869-357-13-7?v=Human+Protein+Atlas
    Average 86 stars, based on 1 article reviews
    brain cancer cell line model ln 229 - by Bioz Stars, 2026-07
    86/100 stars

    Images

    1) Product Images from "CRISPR activation screens map the genomic landscape of cancer glycome remodeling"

    Article Title: CRISPR activation screens map the genomic landscape of cancer glycome remodeling

    Journal: Cell Genomics

    doi: 10.1016/j.xgen.2026.101139

    GAL3ST4 drives Siglec-7 ligand expression in glioma cells (A–C) Graphs depict Kaplan-Meier survival analysis for (A) low-grade glioma (LGG) patients with either high or low mRNA expression of the GAL3ST4 gene, (B) LGG patients with either a high or low chromosomal copy number at the GAL3ST4 locus, and (C) LGG patients with either high or low DNA methylation at the GAL3ST4 promoter. (D) The biosynthetic pathway for either sialylation (ST3GAL1/2) or sulfation (GAL3ST4) of core 1 O-linked glycans is depicted. (E) The average mRNA expression of ST3GAL1, ST3GAL2, and GAL3ST4 across 14 different cancer types is shown. (F) Representative flow cytometry plot depicts staining of the indicated LN-229 cell lines with PNA. (G) Representative flow cytometry plot depicts staining of the indicated LN-229 cell lines with Siglec-7-Fc. (H) Representative flow cytometry plots depict staining of sialidase-treated LN-229 cells with Siglec-7-Fc. (I) The potential structure of a novel sulfated Siglec-7 ligand is depicted.
    Figure Legend Snippet: GAL3ST4 drives Siglec-7 ligand expression in glioma cells (A–C) Graphs depict Kaplan-Meier survival analysis for (A) low-grade glioma (LGG) patients with either high or low mRNA expression of the GAL3ST4 gene, (B) LGG patients with either a high or low chromosomal copy number at the GAL3ST4 locus, and (C) LGG patients with either high or low DNA methylation at the GAL3ST4 promoter. (D) The biosynthetic pathway for either sialylation (ST3GAL1/2) or sulfation (GAL3ST4) of core 1 O-linked glycans is depicted. (E) The average mRNA expression of ST3GAL1, ST3GAL2, and GAL3ST4 across 14 different cancer types is shown. (F) Representative flow cytometry plot depicts staining of the indicated LN-229 cell lines with PNA. (G) Representative flow cytometry plot depicts staining of the indicated LN-229 cell lines with Siglec-7-Fc. (H) Representative flow cytometry plots depict staining of sialidase-treated LN-229 cells with Siglec-7-Fc. (I) The potential structure of a novel sulfated Siglec-7 ligand is depicted.

    Techniques Used: Expressing, DNA Methylation Assay, Flow Cytometry, Staining



    Similar Products

    brain cancer cell line model ln 229  (Human Protein Atlas)
    86
    Human Protein Atlas brain cancer cell line model ln 229
    GAL3ST4 drives Siglec-7 ligand expression in glioma cells (A–C) Graphs depict Kaplan-Meier survival analysis for (A) low-grade glioma (LGG) patients with either high or low mRNA expression of the GAL3ST4 gene, (B) LGG patients with either a high or low chromosomal copy number at the GAL3ST4 locus, and (C) LGG patients with either high or low DNA methylation at the GAL3ST4 promoter. (D) The biosynthetic pathway for either sialylation (ST3GAL1/2) or sulfation (GAL3ST4) of core 1 O-linked glycans is depicted. (E) The average mRNA expression of ST3GAL1, ST3GAL2, and GAL3ST4 across 14 different cancer types is shown. (F) Representative flow cytometry plot depicts staining of the <t>indicated</t> <t>LN-229</t> cell lines with PNA. (G) Representative flow cytometry plot depicts staining of the indicated LN-229 cell lines with Siglec-7-Fc. (H) Representative flow cytometry plots depict staining of sialidase-treated LN-229 cells with Siglec-7-Fc. (I) The potential structure of a novel sulfated Siglec-7 ligand is depicted.
    Brain Cancer Cell Line Model Ln 229, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brain+cancer+cell+line+model+ln+229/pmc13069869-357-13-7?v=Human+Protein+Atlas
    Average 86 stars, based on 1 article reviews
    brain cancer cell line model ln 229 - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    GAL3ST4 drives Siglec-7 ligand expression in glioma cells (A–C) Graphs depict Kaplan-Meier survival analysis for (A) low-grade glioma (LGG) patients with either high or low mRNA expression of the GAL3ST4 gene, (B) LGG patients with either a high or low chromosomal copy number at the GAL3ST4 locus, and (C) LGG patients with either high or low DNA methylation at the GAL3ST4 promoter. (D) The biosynthetic pathway for either sialylation (ST3GAL1/2) or sulfation (GAL3ST4) of core 1 O-linked glycans is depicted. (E) The average mRNA expression of ST3GAL1, ST3GAL2, and GAL3ST4 across 14 different cancer types is shown. (F) Representative flow cytometry plot depicts staining of the indicated LN-229 cell lines with PNA. (G) Representative flow cytometry plot depicts staining of the indicated LN-229 cell lines with Siglec-7-Fc. (H) Representative flow cytometry plots depict staining of sialidase-treated LN-229 cells with Siglec-7-Fc. (I) The potential structure of a novel sulfated Siglec-7 ligand is depicted.

    Journal: Cell Genomics

    Article Title: CRISPR activation screens map the genomic landscape of cancer glycome remodeling

    doi: 10.1016/j.xgen.2026.101139

    Figure Lengend Snippet: GAL3ST4 drives Siglec-7 ligand expression in glioma cells (A–C) Graphs depict Kaplan-Meier survival analysis for (A) low-grade glioma (LGG) patients with either high or low mRNA expression of the GAL3ST4 gene, (B) LGG patients with either a high or low chromosomal copy number at the GAL3ST4 locus, and (C) LGG patients with either high or low DNA methylation at the GAL3ST4 promoter. (D) The biosynthetic pathway for either sialylation (ST3GAL1/2) or sulfation (GAL3ST4) of core 1 O-linked glycans is depicted. (E) The average mRNA expression of ST3GAL1, ST3GAL2, and GAL3ST4 across 14 different cancer types is shown. (F) Representative flow cytometry plot depicts staining of the indicated LN-229 cell lines with PNA. (G) Representative flow cytometry plot depicts staining of the indicated LN-229 cell lines with Siglec-7-Fc. (H) Representative flow cytometry plots depict staining of sialidase-treated LN-229 cells with Siglec-7-Fc. (I) The potential structure of a novel sulfated Siglec-7 ligand is depicted.

    Article Snippet: To test this hypothesis, we used the Human Protein Atlas to select a brain cancer cell line model (LN-229) with representative expression of GAL3ST4.

    Techniques: Expressing, DNA Methylation Assay, Flow Cytometry, Staining